Similis Bio Nominated for Two Prestigious Global Generics & Biosimilars Awards

The awards recognize the continued success of Similis Bio, a JSR Life Sciences business unit, in advancing the biosimilar development field.

SUNNYVALE, California 25 October, 2023 – JSR Life Sciences, LLC (JSR) today announces that Similis Bio (“Similis”), its business unit focused on biosimilar development, has been nominated for two awards at the upcoming Global Generics & Biosimilars Awards 2023. The awards, co-locating with CPhI Worldwide in Barcelona, provide a unique opportunity for the industry to recognize innovation and future opportunities while shining a light on the companies and individuals driving positive change.

“We are honored to be nominated as finalists for two awards after only one year in business,” said John Gabrielson, Senior Vice President at JSR Life Sciences and Head of Similis Bio. “I thank our employees, for their tireless commitment to our mission, and our dedicated partners who challenge us every day to find better ways of making biologics more accessible worldwide. As an industry, we need to deliver safe, effective, and affordable medicines to everyone who needs them, without exception. Fulfilling this promise to patients will take the best efforts from all of us: scientists, drug developers, thought leaders, and policy makers.”

Similis Bio was nominated in two categories: Biosimilar Initiative of the Year which recognizes initiatives aimed at increasing biosimilar usage, and Business Development of the Year which recognizes non-acquisition transactions in the biosimilar space. Winners will be announced at the award ceremony in Barcelona on 25 October 2023.

JSR launched Similis Bio to mitigate the innate barriers to market entry for biosimilars and promote more productive development programs. Similis provides biosimilar drug developers with technology to accelerate development timelines and lower costs. By offering complete

analytical and process development packages, Similis supplies companies with data to determine an appropriate biosimilar target and accelerate early program development. Data packages include reference product data, analytical procedures, process expertise, and CMC templates from a centralized model designed to give partners access to higher quality biosimilars at a lower cost than other development models.

A business unit of JSR Corporation, JSR Life Science LLC is changing human health as a strategic partner and pathfinder for the life sciences industry. Rooted in a history of materials innovation, JSR LS provides specialized products, materials, and services to biopharmaceutical companies and academic researchers. Together with its world-class affiliates, JSR LS offers best-in-class integrated services that de-risk molecule selection, accelerate biologic development timelines, increase clinical success rates, and develop novel in vitro diagnostics. JSR LS’s global network of affiliates includes Crown Bioscience, KBI Biopharma, Inc., and MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. The company operates R&D and applications labs, manufacturing facilities, and sales offices worldwide. For more information, visit JSRLifeSciences.com